The Impax Study
Access Clinical Trials is conducting a Pediatric Migraine Trial ages 6 - 11. This is a double blind, placebo controlled, crossover study to evaluate the efficacy and safety of Zolmitriptan nasal spray, marketed under the name Zomig. The study has an open label extension. Zomig is a nasal spray produced by AstraZeneca, and is already FDA approved for children 12 - 18.
There is no cost to participate in this study, and no insurance is needed. Study participants will be compensated for enrollment in this study.
Jaclyn Brooks is the Sub-Investigator on the Pediatric Migraine Study at Access Clinical Trials, Inc. In addition to being CEO of the company, Jaclyn is a registered nurse with many years of pediatric clinical experience. Since founding Access Clinical Trials in 1999, she has earned extensive training and certifications in the area of Pediatric Neurology. Jaclyn has conducted numerous Pediatric Neurology Trials since 2007.
Dr. James Fry is the Principal Investigator on the Pediatric Migraine Study at Access Clinical Trials, Inc.. Dr. Fry earned his Doctor of Medicine Degree from Texas Tech Health Science Center in 1985. Since joining Access in 2006 he has obtained extensive training and certifications in various areas of Pediatric Neurology Dr. Fry is a current member of the Child Neurology Society, American Academy of Neurology, Southern Medical association, and the American Headache Society. Contact: Midtown Pediatric Neurology
Carol Arvin, RNC NP is a Sub-Investigator for the Pediatric Migraine Study. Carol has done extensive work with evaluation and treatment protocols of headache management with several neurologists in the Nashville medical community.
Taneka Sullins is the Primary Study Coordinator of the Pediatric Migraine Study at Access Clinical Trials Inc. Taneka is a certified Clinical Medical Assistant, having earned her Associate Degree of Science from Miller Motte Technical College in 2015. She has extensive training in Pediatric Neurology Trials, and works closely with Dr. Fry.